52 results about "Radioactive labeling" patented technology

Methods and kits are provided for detecting the presence or absence of target nucleic acid sequences in a sample. The methods and kits involve the use of negatively charged nanoparticles and the electrostatic interactions between the metal nanoparticles and nucleic acid molecules. The methods rely upon the differential interaction of ss-nucleic acids and ds-nucleic acids with the negatively charged nanoparticles that differentiate between tagged oligonucleotide probes that hybridize with a target and those that do not. Improvements in sensitivity for a fluorescent variation of the method have been obtained by including a step of separating the ds-nucleic acids in solution from the negatively charged nanoparticles to which ss-nucleic acids have been bound, and then detecting for the presence of the ds-target nucleic acids in the solution. The same separation protocols can be used to make the detection approach viable with electrochemical or radioactive tags.

The present invention relates to nuclear medicine using fluorescent silica nanoparticle and detecting method of optical dual imaging, and more particularly to radioisotope labeled fluorescent silica nanoparticles which are used for PET (positron emission tomography) and fluorescence detecting, and detecting method of PET and fluorescent dual imaging using thereof. Functionalized silica nanoparticles of this invention have promising potential as a role for organic lymphatic tracer in biomedical imaging such as pre- and intra-operative surgical guidance.

The invention discloses a Cr-doped perovskite structure halide near infrared light-emitting material and a preparation method thereof. The chemical composition is AB1-xX3:xCr<3+>, wherein A:B:X is equal to 1:1:3; A is at least one of Cs and Rb; B is at least one of Ag, Na, In, Ga and Pb; X is at least one of Cl and Br; and x is more than 0 and less than 100 mole percent. The invention also discloses the preparation method of the near infrared light-emitting material. The preparation method comprises the following steps: (1) weighing materials: weighing an A-containing compound, a B-containingcompound and a Cr-containing compound separately; and (2) grinding and uniformly mixing the materials and performing high-temperature calcining synthesis by a solid phase method. An emission band of the near infrared light-emitting material is positioned at 800 to 1400 nm and the emission peak is positioned at about 950 to 1050 nm. The preparation method is simple in process, low in raw material price, easy in large-scale technical promotion and is of great importance in research and development of near infrared fluorescent powder with wide spectrum emission. The light-emitting material can beused for manufacturing near infrared light-emitting devices and can be applied in the fields of spectral transformation, radioactive labeling, anti-faking and the like.

A method for conducting a receptor-ligand association reaction includes the steps of pressurizing a reaction solution containing a ligand or receptor labeled with a labeling substance such as a radioactive labeling substance, a fluorescent substance or a labeling substance which generates chemiluminescence emission when it contacts a chemiluminescent substrate and forcibly feeding the reaction solution so as to cut through a plurality of absorptive regions formed in a biochemical analysis unit to be spaced from each other and containing receptors or ligands, thereby selectively associating the ligand or receptor contained in the reaction solution with the receptors or ligands contained in the absorptive regions of the biochemical analysis unit. According to this method, it is possible to efficiently associate a ligand or receptor with receptors or ligands fixed in the absorptive regions of the biochemical analysis unit and produce biochemical analysis data having an excellent quantitative characteristic with good repeatability.

The invention relates to a rare earth fluorescent signal based quantitative detection method of HPA (hydroxyapatite) nano particles, and the quantitative detection method is characterized by comprising the following steps: 1) formulating a europium ion fluorescence-concentration standard curve; 2) establishing dissolution rate of calcium ions and europium ions in the HPA (hydroxyapatite) nano particles, and determining the accuracy of a fluorescence-concentration standard curve method; 3) quantitatively detecting intracellular HAP nano particles; and 4) tracing a dissolution course of the intracellular HAP nano particles. The main advantages of the quantitative detection method are that: 1) the quantitative detection method is good in biocompatibility, safe and reliable, and is free of radioactive labeling using condition limitation problems; 2) the quantitative detection method is low in the detection limit, the detection limit concentration can reach 0.5nM, and the sample needing amount is less; and 3) the quantitative detection method can more accurately shown dissolution of the intracellular HAP nano particles, and the compatibility of the dissolving out of the europium ions and the dissolution of the HAP nano particles is high.

The invention discloses a novel radioactive labeling method for a fluoboric acid compound. The method comprises the following steps: (1) adopting a proton circular accelerator for performing <18>O(p, n)<18>F reaction and generating <18>F<->; (2) transmitting <18>F<-> into an anion exchange column QMA through a pipeline, thereby capturing by QMA; (3) drying the QMA by blowing N2 and then concentrating and eluting the <18>F<-> with hydrochloric acid and sodium chloride solution till entering into a reaction flask; (4) performing ion exchange reaction on [<19>F] fluoboric acid compound, ethanol solution and the concentrated <18>F<-> at 90 DEG C, and then adding 5mL deionized water into an ion exchange reaction system and performing quenching reaction; and (5) purifying the reaction system through a neutral Al2O3 column, and then dropping into 5mL disodium hydrogen phosphate-citrate buffer solution with pH=7, thereby acquiring [<18>F] fluoboric acid compound solution. According to the invention, the hydrochloric acid and sodium chloride solution are firstly adopted for eluting and concentrating <18>F<->, the eluting efficiency of the <18>F<-> can be guaranteed and the acidic condition in reaction can be guaranteed; the safety factor is high; the residue of organics, such as, polyether polyamine and acetonitrile, need not be checked; the fluoboric acid compound solution can be directly used as an injection solution; the operation is simple; the purification is fast; and the product yield is high.

A novel analytical method involves labeling samples with different radioactive labeling agents, mixing and subjecting the mixture to any separation technique, and then differentially detecting and quantifying subcomponents from each sample for comparison. The novel technique exploits the differences in radiation energy or half-life between isotopes to make differential detection and quantification of labels possible. Detailed methods for differential detection and quantification are also described as well as the construction and application of hardware and software to enable and enhance such a process. This method is useful in finding molecular differences between two samples in differential proteomics, phosphor-proteomics, glycomics, metabolomics, transcriptomics, genomics and diagnostic applications.

The invention is directed to methods for the non-radioactive labeling, detection, quantitation and isolation of nascent proteins translated in a cellular or cell-free translation system. tRNA molecules are misaminoacylated with non-radioactive markers which may be non-native amino acids, amino acid analogs or derivatives, or substances recognized by the protein synthesizing machinery. Markers may comprise cleavable moieties, detectable labels, reporter properties wherein markers incorporated into protein can be distinguished from unincorporated markers, or coupling agents which facilitate the detection and isolation of nascent protein from other components of the translation system. The invention also comprises proteins prepared using misaminoacylated tRNAs which can be utflized in pharmaceutical compositions for the treatment of diseases and disorders in humans and other maninials, and kits which may be used for the detection of diseases and disorders.

The invention relates to a radionuclide-labeled glucose derivative molecular probe and application thereof, and belongs to the technical field of nuclear medicine. According to the present invention, propargyl glycine is used to synthesize an amino acid skeleton, and the amino acid skeleton reacts with glucose azide to prepare a series of radionuclide-labeled glucose derivative molecular probes, such as [68Ga] Ga-NOTA-SDG, [68Ga] Ga-NOTA-DDG, [68Ga] Ga-NOTA-TDG, [68Ga] Ga-DOTA-SDG, [68Ga] Ga-DOTA-DDG and the like; the glucose derivative molecular probe labeled by the series of radionuclides has the advantages of being simple and rapid in labeling, high in radiolabeling yield and good in stability, can accurately position tumors, has good tumor uptake and lower non-target tissue uptake, and has great application prospects in preparation of broad-spectrum tumor imaging agents.

The invention is directed to methods for the non-radioactive labeling, detection, quantitation and isolation of nascent proteins translated in a cellular or cell-free translation system. tRNA molecules are misaminoacylated with non-radioactive markers which may be non-native amino acids, amino acid analogs or derivatives, or substances recognized by the protein synthesizing machinery. Markers may comprise cleavable moieties, detectable labels, reporter properties wherein markers incorporated into protein can be distinguished from unincorporated markers, or coupling agents which facilitate the detection and isolation of nascent protein from other components of the translation system. The invention also comprises proteins prepared using misaminoacylated tRNAs which can be utilized in pharmaceutical compositions for the treatment of diseases and disorders in humans and other mammals, and kits which may be used for the detection of diseases and disorders.

The invention discloses the use of nitrasin-based pharmaceutical C60-benzoic acid chlorethazine using C60 as the carrying agent in the preparation of anti-tumor agents, which has a structural formula I. It is found by the radioactive labeling technique employed in the invention that C60-benzoic acid chlorethazine has high assimilation ratio and longer detention time in stomach, and can improve the eradication action to the body tumor tissue, the tumor-resisting rate is higher than that of the chlorethazine for lymph metastasis.

Applicants have discovered that an inexpensive marker tape can be made from some of the components used in applicants Signal Tape disclosed in PCT / US2017 / 050405. This marker tape, called Spartan Marker Tape, has elongated upper and lower protective layers made from a thermoplastic material which are laminated together with a locating device inside the laminated layers. Various locating devices may be used in the Spartan Marker Tape, such as conventional RF or RFID tags. In addition, magnetic tags, or radioactive tags may be used. Of course, classis marker wire may also be used as a locating device.

The invention provides a preparation method of Al18F tracer integrated freeze-dried powder, a kit and application thereof, and the preparation method comprises the following steps: dissolving 1-10 mg of a precursor by using deionized water, adding a pH buffer solution with the concentration of 0.2-0.5 M and an AlCl3 solution with the concentration of 10 mM, with the ratio of the amount of substance of AlCl3 to the amount of substance of the precursor being 0.8-1.0, then continuously adding a stabilizer solution with the concentration of 0.5 M and 1-4 mg of an excipient, and uniformly stirring to obtain the Al18F tracer integrated freeze-dried powder. And finally, adding deionized water to enable the concentration of the precursor to be 0.5-1.0 mM, uniformly mixing the solution, sub-packaging the solution into 1.5 mL cryopreservation tubes or 2 mL penicillin bottles according to a certain volume, and then putting the cryopreservation tubes or the penicillin bottles into a vacuum freeze dryer to remove water at a low temperature to obtain powder or freeze-dried cakes, and the container is a freeze-dried powder / cake storage container and is used for storing the freeze-dried powder / cakes. Meanwhile, the reaction container is also used during radioactive labeling.

The invention discloses a radioactive labeling method of [18F] trifluoromethyl terminal olefin in the technical field of organic synthesis, under the condition of room temperature, 3, 3-difluoroallyl sulfosalt is used as a precursor, [18F] KF / K222 or [18F] TBAF is used as a fluorinating reagent, acetonitrile is used as a solvent, very high radiochemical yield can be obtained within 30 seconds, the tolerance of functional groups is excellent, and the method is suitable for industrial production. The specific reaction formula is as follows: # imgabs0 #. The method provides a simple and efficient way for producing the [18F] trifluoromethylated terminal olefin compound, so that the [18F] trifluoromethylated terminal olefin compound can be applied to positron emission tomography imaging. According to the method for preparing the 3, 3-difluoroallyl sulfur salt compound, the raw materials are easy to obtain, the cost is low, the operation is simple and convenient, safety and controllability are realized, and the radiation yield of the obtained product is high.

The invention belongs to the field of tumor drugs, and discloses a radioactive hydrogel based on crosslinking of sodium alginate and metal ions and a preparation method and application thereof.The preparation method of the radioactive hydrogel comprises the following steps that lutetium chloride and metal ions are mixed, and a metal ion mixed solution is obtained; doping 177Lu radioactive isotope into the obtained metal ion mixed solution to obtain a metal ion cross-linking agent; and injecting a metal ion cross-linking agent into the sodium alginate solution under a vortex condition, centrifuging, and discarding the supernatant to obtain the radioactive hydrogel. The radioactive hydrogel (177Lu-RH) provided by the invention has good in-tumor colonization capability, can be directly injected into a tumor to realize local radiotherapy, has good radioactive stability, and can be stably retained at a tumor part for more than 120 hours, so that the stability of radioactive labeling in a treatment process is ensured.

The invention of the application discloses a nonradioactive labeling immunoprecipitation method for detecting an NXP2 autoantibody of inflammatory myopathies and application. A plasma pCMV-myc-NXP2N or pCMV-myc-NXP2C which comprises an NXP2 N end (1-500aa) or an NXP2 C end (400-939aa) and has a Myc tag is constructed, an HEK293 cell is transiently transfected, a serum of an inflammatory myopathies patient with positive NXP2 autoantibody is subjected to immunoprecipitation with an HEK293 cell lysis buffer with an overexpressed NXP2 N end or an NXP2 C end, the NXP2 N end or the NXP2 C end is found to be precipitated by the NXP2 autoantibody, the to-be-detected serum of the inflammatory myopathies patient is subjected to immunoprecipitation with the HEK293 cell lysis buffer with the overexpressed NXP2 C end, then SDS-PAGE gel electrophoresis is implemented, and the precipitated NXP2 C end is detected by a c-myc antibody to determine whether the NXP2 autoantibody exists in the serum of the inflammatory myopathies patient. The problem that no immunoblotting membrane strip or ELISA (Enzyme-Linked Immuno Sorbent Assay) kit for commercially detecting the NXP2 autoantibody exists in the domestic at present is solved, and the problems of high cost of the ELISA kit autonomously coating an NXP2 antigen, high false positive rate, safety of a radioactive labeling immunoprecipitation method and the like are solved.

The invention is directed to methods for the non-radioactive labeling, detection, quantitation and isolation of nascent proteins translated in a cellular or cell-free translation system. tRNA molecules are misaminoacylated with non-radioactive markers which may be non-native amino acids, amino acid analogs or derivatives, or substances recognized by the protein synthesizing machinery. Markers may comprise cleavable moieties, detectable labels, reporter properties wherein markers incorporated into protein can be distinguished from unincorporated markers, or coupling agents which facilitate the detection and isolation of nascent protein from other components of the translation system. The invention also comprises proteins prepared using misaminoacylated tRNAs which can be utilized in pharmaceutical compositions for the treatment of diseases and disorders in humans and other mammals, and kits which may be used for the detection of diseases and disorders.

Provided are a humanized / fully human HER2 antibody or an antigen-binding fragment thereof, and an antibody-radionuclide conjugate using same as a targeting group for radioactive labeling, showing a tumor-targeting enrichment ability.

A nerve injury diagnosis developer belongs to the technical field of nuclear medicine molecular imaging, and is characterized in that polypeptide NP41 is used as a substrate, a radioactive precursor compound is synthesized through covalent linkage with a chelating group NOTA, and then a novel radioactive developer 68Ga-NOTA-NP41 is synthesized through radioactive labeling of the radioactive precursor compound and 68Ga radioactive label. The 68Ga-NOTA-NP41 developer obtained by the invention can be used for performing specific imaging on nerve extracellular matrix protein in a living body level and specificity so as to realize positioning of a nerve injury focus of an organism. After application, the kit is high in sensitivity, strong in specificity, good in stability, obvious in target organ development, high in accuracy and not prone to false positive.

The invention discloses a superfine degradable solid tracer agent for oil field logging and a preparation method of the superfine degradable solid tracer agent. According to the method, a natural degradable biomass material is used as a raw material, and the degradable solid tracer agent with the particle size smaller than 100 micrometers is prepared through the steps of pretreatment, gamma-ray irradiation, enzymatic hydrolysis of polysaccharide hydrolase and saccharifying enzyme, freeze drying, radioisotope labeling, surface coating, antistatic treatment and the like. In the coating process, particles are coated with a hydrophobic coating solution, and then antistatic treatment is performed to improve the dispersity and stability of the particles. By optimizing the treatment process of the biomass material, the structural stability and processing adaptability of the tracer agent are enhanced, and the tracer agent is particularly suitable for oil field logging of low-permeability strata and heterogeneous strata. The tracer agent has a good radioactive labeling effect, particle size distribution and environmental protection characteristics, meets the measurement precision requirement in an oil field environment, can be naturally degraded after being used, and reduces negative effects on the environment.

The invention provides a preparation method of alpha-type 2-amino-dihydrotetrabenazine, which comprises the following steps: 1) reacting raw materials containing tetrabenazine, ammonium acetate and sodium cyanoborohydride, and post-treating a reaction mixed solution to obtain a crude product; (2) carrying out column chromatography on the crude product in the step (1), and separating to obtain alpha-type 2-amino-dihydrotetrabenazine; a stationary phase used by the column chromatography is silica gel; the diameter-height ratio of the stationary phase is 1: (6-8), a mixed solution of dichloromethane and methanol is adopted as an elution system, and the volume ratio of dichloromethane to methanol is (9-11): 1; the elution flow rate is 4 to 6 mL / min. Radioactive labeling of the alpha-type 2-amino-dihydrotetrabenazine is realized through a fluorine [< 18 > F] labeling technology, a key technical support is provided for development of a novel positron emission tomography (PET) specific tracing probe based on a molecular skeleton, and an important technical foundation is laid for development of a novel VMAT2 targeted tracing probe based on a compound skeleton.

A thio-selective radioactive labeling agent has the following general formula:*R-L-VS,wherein said *R is a radioisotope, L is a linking group, and VS is a vinylsulfone functional group.

The invention discloses a Cr-doped perovskite structure halide near infrared light-emitting material and a preparation method thereof. The chemical composition is AB1-xX3:xCr<3+>, wherein A:B:X is equal to 1:1:3; A is at least one of Cs and Rb; B is at least one of Ag, Na, In, Ga and Pb; X is at least one of Cl and Br; and x is more than 0 and less than 100 mole percent. The invention also discloses the preparation method of the near infrared light-emitting material. The preparation method comprises the following steps: (1) weighing materials: weighing an A-containing compound, a B-containingcompound and a Cr-containing compound separately; and (2) grinding and uniformly mixing the materials and performing high-temperature calcining synthesis by a solid phase method. An emission band of the near infrared light-emitting material is positioned at 800 to 1400 nm and the emission peak is positioned at about 950 to 1050 nm. The preparation method is simple in process, low in raw material price, easy in large-scale technical promotion and is of great importance in research and development of near infrared fluorescent powder with wide spectrum emission. The light-emitting material can beused for manufacturing near infrared light-emitting devices and can be applied in the fields of spectral transformation, radioactive labeling, anti-faking and the like.

The present invention provides a nucleic acid aptamer targeting TSHR protein, a nucleic acid derivative and its application, and belongs to the field of molecular biology technology. The nucleic acid aptamer targeting TSHR protein in the present invention comprises a nucleotide sequence as shown in SEQ ID NO.1, and one or more modifications including radioactive labeling, therapeutic drug connection, fluorescent labeling or biotin labeling are performed on both ends or one end of the nucleic acid aptamer targeting TSHR protein to obtain a nucleic acid aptamer targeting TSHR protein and its derivatives. The nucleic acid aptamer and its derivatives in the present invention can identify and target cells expressing thyrotropin receptors, have high affinity, strong stability, low cost, and have the advantages of in vitro and in vivo imaging labeling functions, providing new molecular tools for the diagnosis and treatment of thyroid diseases and thyroid-related eye diseases.

The present invention relates to methods for the preparation of chemically aminoacylated tRNAs for the purpose of introduction of markers into nascent proteins. The present invention also relates to methods for the non-radioactive labeling, detection, quantitation and isolation of nascent proteins translated in a cellular or cell-free translation system utilizing chemically aminoacylated tRNAs. tRNA molecules are misaminoacylated with non-radioactive markers which may be non-native amino acids, amino acid analogs or derivatives. Markers may comprise cleavable moieties, detectable labels, reporter properties wherein markers incorporated into protein can be distinguished from unincorporated markers, or coupling agents which facilitate the detection and isolation of nascent protein from other components of the translation system.

A biochemical analysis unit includes a substrate made of a material capable of attenuating radiation energy and / or light energy and formed with a plurality of holes, and a plurality of absorptive regions formed by forming an absorptive region in every hole. According to the thus constituted biochemical analysis unit, even in the case where the absorptive regions are formed at a high density, when a stimulable phosphor layer formed on a stimulable phosphor sheet is exposed to a radioactive labeling substance contained in the plurality of absorptive regions, electron beams (β rays) released from the radioactive labeling substance contained in the individual absorptive regions are reliably prevented from being scattered in the substrate and advancing to regions of the stimulable phosphor layer that should be exposed to electron beams released from absorptive regions formed in neighboring holes. Therefore, it is possible to efficiently prevent noise caused by the scattering of electron beams released from the radioactive labeling substance from being generated in biochemical analysis data produced by irradiating the stimulable phosphor layer exposed to the radioactive labeling substance with a stimulating ray and photoelectrically detecting stimulated emission released from the stimulable phosphor layer and to produce biochemical analysis data having a high quantitative accuracy.

The invention discloses a gene detection probe and a gene detection method, and particularly relates to the technical field of gene detection.AuNPs with the surface wrapped with citric acid is prepared by adopting a Turkevich-Frens method, and meanwhile, AuNPs capable of being connected with target DNA modified sulfydryl through non-covalent electrostatic interaction and connected with citric acid through the non-covalent electrostatic interaction is prepared by continuously covering the surface with part of digoxin organic markers; on the basis of matching with labeled deoxynucleotide with target DNA surface radioactivity of 2-10 [mu] Ci, a DNA probe integrating fluorescent labeling, radioactive labeling and metal particles is prepared. Probe particles contain a large number of fluorescent small molecules and a small number of metal ions, the metal ions stabilize the particles by increasing surface charges, the particles are dissolved to generate fluorescent signals, signal amplification is achieved compared with a small molecule fluorophore, and the probe has good single-base mismatch sequence distinguishing capacity through cooperation of three kinds of detection. The influence of single biotin quenching on a detection result can be reduced, and the overall use reliability is improved.

Applicants have discovered that an inexpensive marker tape can be made from some of the components used in applicants Signal Tape disclosed in PCT / US2017 / 050405. This marker tape, called Spartan Marker Tape, has elongated upper and lower protective layers made from a thermoplastic material which are laminated together with a locating device inside the laminated layers. Various locating devices may be used in the Spartan Marker Tape, such as conventional RF or RFID tags. In addition, magnetic tags, or radioactive tags may be used. Of course, classis marker wire may also be used as a locating device.

The invention relates to a rare earth fluorescent signal based quantitative detection method of HPA (hydroxyapatite) nano particles, and the quantitative detection method is characterized by comprising the following steps: 1) formulating a europium ion fluorescence-concentration standard curve; 2) establishing dissolution rate of calcium ions and europium ions in the HPA (hydroxyapatite) nano particles, and determining the accuracy of a fluorescence-concentration standard curve method; 3) quantitatively detecting intracellular HAP nano particles; and 4) tracing a dissolution course of the intracellular HAP nano particles. The main advantages of the quantitative detection method are that: 1) the quantitative detection method is good in biocompatibility, safe and reliable, and is free of radioactive labeling using condition limitation problems; 2) the quantitative detection method is low in the detection limit, the detection limit concentration can reach 0.5nM, and the sample needing amount is less; and 3) the quantitative detection method can more accurately shown dissolution of the intracellular HAP nano particles, and the compatibility of the dissolving out of the europium ions and the dissolution of the HAP nano particles is high.